Helix Biomedix Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2012. For the quarter, the company reported total revenue of $469,071 against $394,707 a year ago. Loss from operations was $748,173 against $591,091 a year ago. Net loss and comprehensive loss was $785,184 or $0.02 per basic and diluted share against $605,617 or $0.01 per basic and diluted share a year ago. The increase in net loss reflects higher operating expenses and professional fees. Revenue in the third quarter reflected an increase in peptide and consumer product sales and license fees, offset by a decrease in sales to NuGlow Cosmaceuticals, LLC.

For the nine months, the company reported total revenue of $1,620,015 against $1,445,438 a year ago. Loss from operations was $1,878,387 against $1,859,323 a year ago. Net loss and comprehensive loss was $2,035,321 or $0.04 per basic and diluted share against $1,940,226 or $0.04 per basic and diluted share a year ago.